Kyverna Therapeutics, Inc. (KYTX) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kyverna Therapeutics, Inc. successfully launched its initial public offering (IPO), issuing 16.675 million shares at $22 each, raising $366.9 million before expenses. Concurrently, the company restructured its corporate governance, authorizing 490 million shares of common stock and creating 10 million shares of flexible preferred stock. It introduced measures to strengthen board control, such as requiring a two-thirds majority for director removal and bylaw amendments, eliminating cumulative voting, and barring action by written consent. The company also designated Delaware courts for internal legal disputes and federal courts for Securities Act claims.
For further insights into KYTX stock, check out TipRanks’ Stock Analysis page.